12 completed, 2 active not recruiting, 1 withdrawn. 8 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 7 | Completed 7 |
Follow MF59: new trials by email Literature Review of MF59 trials Research Report on MF59
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine | Phase 1 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 80 | 2025-11-13 | 2026-02-19 |
| Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older Quadrivalent Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine | Phase 1 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 80 | 2025-11-13 | 2026-02-19 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 372 | 2018-11-02 | 2021-05-17 |
| Panblok H7 Vaccine Adjuvanted With AS03 or MF59 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7 - Influenza, Human | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 366 | 2017-09-20 | 2020-05-06 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology AS03, MF59, Monovalent Influenza A/H5N8 vaccine - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 388 | 2017-01-09 | 2024-09-23 |
| Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk) - A/Vietnam/H5N1 Influenza Virus | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 422 | 2016-03-01 | 2020-08-31 |
| H7N9 Mix and Match With MF59 in Healthy Elderly Persons MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 479 | 2014-10-01 | 2017-07-06 |
| H7N9 Mix and Match With MF59 in Healthy Adults Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 700 | 2013-09-01 | 2016-12-12 |
| H7N9 Mix and Match With AS03 and MF59 in Healthy Adults AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 980 | 2013-09-01 | 2017-07-06 |
| Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients CAD106, Placebo, Alum - Alzheimer's Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 177 | 2010-03-01 | 2021-03-05 |
| Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo) MF59, rgp120/HIV-1 SF-2 - HIV Infections, Pregnancy | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-01 | ||
| A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59 - HIV Infections, HIV Seronegativity | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2021-10-28 | |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 112 | 2021-11-04 | |
| A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers MF59, rgp120/HIV-1 SF-2 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2021-11-04 | |
| A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3 Aluminum hydroxide, MF59, rgp120/HIV-1IIIB - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 130 | 2021-11-04 |
Influenza, Human (8) · HIV Infections (5) · Influenza in Birds (4) · AIDS-Related Complex (2) · Alzheimer Disease (1) · Central Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Orthomyxoviridae Infections (1) · Pregnancy Complications, Infectious (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (10) · Ab&B Bio-tech Co., Ltd.JS (2) · Biomedical Advanced Research and Development Authority (2) · Novartis Pharmaceuticals (1)
United States (12) · China (2) · Belgium (1) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Norway (1) · Spain (1) · Sweden (1) · Switzerland (1)
Yeqing Tong, Doctor (2) · Allen M (1) · Carlos Fierro, MD (1) · Corey L (1) · D Schwartz (1) · M Clements (1) · Mark Adams, MD (1) · Matthew Davis, MD (1) · McElrath J (1) · Schooley RT (1) · Scott GB (1) · Silverman N (1) · Starr S (1) · Terry Poling, MD (1)
PMID 25291577, PMID 26197184, PMID 36273986, PMID 39798434
2009 (1)